A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-01-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT00202982
- Locations
- 🇺🇸
The MS Center of Atlanta, Atlanta, Georgia, United States
🇺🇸Michigan Institute of Neurological Disorders, Farmington Hills, Michigan, United States
🇺🇸Center for Neurologic Study, La Jolla, California, United States
Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00203099
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 208
- Registration Number
- NCT00203021
- Locations
- 🇺🇸
Teva Investigational Site 009, Los Angeles, California, United States
🇺🇸Teva Investigational Site 004, Los Angeles, California, United States
🇺🇸Teva Investigational Site 008, New Haven, Connecticut, United States
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-10-18
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT00202995
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00203073
A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT00203125
Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00203112
Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 306
- Registration Number
- NCT00203138
A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 340
- Registration Number
- NCT00203151
A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-10-18
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 2106
- Registration Number
- NCT00203008
© Copyright 2024. All Rights Reserved by MedPath